A detailed history of Yousif Capital Management, LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Yousif Capital Management, LLC holds 47,458 shares of ARWR stock, worth $931,600. This represents 0.01% of its overall portfolio holdings.

Number of Shares
47,458
Previous 53,415 11.15%
Holding current value
$931,600
Previous $1.39 Million 33.86%
% of portfolio
0.01%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$19.36 - $29.54 $115,327 - $175,969
-5,957 Reduced 11.15%
47,458 $918,000
Q2 2024

Jul 31, 2024

SELL
$21.87 - $28.24 $86,998 - $112,338
-3,978 Reduced 6.93%
53,415 $1.39 Million
Q1 2024

Apr 26, 2024

BUY
$27.21 - $39.48 $140,648 - $204,072
5,169 Added 9.9%
57,393 $1.64 Million
Q4 2023

Feb 01, 2024

BUY
$21.2 - $31.03 $35,170 - $51,478
1,659 Added 3.28%
52,224 $1.6 Million
Q3 2023

Oct 30, 2023

SELL
$26.2 - $36.08 $71,395 - $98,318
-2,725 Reduced 5.11%
50,565 $1.36 Million
Q2 2023

Aug 02, 2023

SELL
$25.16 - $41.38 $58,421 - $96,084
-2,322 Reduced 4.18%
53,290 $1.9 Million
Q1 2023

May 02, 2023

BUY
$23.68 - $38.51 $26,474 - $43,054
1,118 Added 2.05%
55,612 $1.41 Million
Q4 2022

Jan 09, 2023

SELL
$28.0 - $40.56 $14,000 - $20,280
-500 Reduced 0.91%
54,494 $0
Q3 2022

Nov 04, 2022

SELL
$29.63 - $48.31 $152,179 - $248,120
-5,136 Reduced 8.54%
54,994 $1.82 Million
Q2 2022

Aug 01, 2022

BUY
$27.79 - $50.61 $98,793 - $179,918
3,555 Added 6.28%
60,130 $2.12 Million
Q1 2022

May 12, 2022

BUY
$39.62 - $69.97 $94,057 - $166,108
2,374 Added 4.38%
56,575 $2.6 Million
Q4 2021

Jan 31, 2022

BUY
$58.09 - $82.51 $3.15 Million - $4.47 Million
54,201 New
54,201 $3.59 Million

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.08B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Yousif Capital Management, LLC Portfolio

Follow Yousif Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Yousif Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Yousif Capital Management, LLC with notifications on news.